{"id":2530,"date":"2017-07-04T00:00:00","date_gmt":"2017-07-03T22:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/"},"modified":"2019-01-13T16:38:48","modified_gmt":"2019-01-13T15:38:48","slug":"04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/","title":{"rendered":"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer"},"content":{"rendered":"<p><span><strong>Berlin, Germany, July 4, 2017<\/strong> &#8211; NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, announced today that the first patients were treated in its Phase 1\/2 clinical trial in patients with metastatic colorectal and pancreatic cancer at the National Center for Tumor Diseases in Heidelberg, Germany. The goal of the trial is to evaluate safety and the effects of NOX-A12 (olaptesed pegol) as a monotherapy on immune cell infiltration into tumors in addition to safety and efficacy of NOX-A12 in combination with Keytruda\u00ae (pembrolizumab), a programmed death receptor-1 (PD-1) immune checkpoint-inhibiting antibody marketed by Merck &amp; Co.\/MSD.<\/span><\/p>\n<p>NOXXON and Merck &amp; Co.\/MSD (NYSE: MRK) collaborated closely in the two-arm clinical trial design (ClinicalTrials.gov; Identifier: NCT03168139) that is composed of two parts: patients will receive NOX-A12 monotherapy for two weeks, followed by combination therapy of NOX-A12 plus Keytruda\u00ae for up to two years. The open-label trial is designed to include 20 patients, 10 patients for each metastatic pancreas and colorectal cancer.<\/p>\n<p>Two patients have now completed part 1 of the trial in which they received NOX-A12 monotherapy for two weeks. Data from this stage will be used to analyze safety and, through tumor biopsies taken before and after NOX-A12 treatment, the ability of NOX-A12 to modulate the tumor microenvironment including the number of T-cells present in the tumors. Part 1 could, as such, provide clinical data to support the broad potential applicability for combinations of NOX-A12 not only with checkpoint inhibitors but also other T-cell based therapeutics such as CAR-T approaches. If successful, this avenue of therapeutic intervention could potentially become game-changing for a wide range of cancers. Both patients that completed part 1 have now progressed into part 2, receiving NOX-A-12 in combination with Keytruda\u00ae. Top-line data for all 20 patients from part 1 is targeted to be available in Q2 2018, and initial response-rate data in Q4 2018.<\/p>\n<p>\u201cWe believe that our lead product NOX-A12 has the potential to transform cancer types that are resistant to checkpoint inhibitor therapy into checkpoint inhibitor sensitive tumors. We would like to thank the team at the National Center for Tumor Diseases in Heidelberg (Germany) for the excellent start to this trial, which will provide us with the first human data to test this hypothesis,\u201d said Jarl Ulf Jungnelius, Chief Medical Officer of NOXXON Pharma. \u201cOur interactions with the Merck team and the strong preclinical data we have generated underscore NOX-A12\u2019s potential as a future component of innovative treatment for patients suffering from colorectal and pancreatic cancers.\u201d<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2530\" data-postid=\"2530\" class=\"themify_builder_content themify_builder_content-2530 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12<\/p>\n","protected":false},"author":1,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-03T22:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:38:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer\",\"datePublished\":\"2017-07-03T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/\",\"url\":\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/\",\"name\":\"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2017-07-03T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12","og_url":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2017-07-03T22:00:00+00:00","article_modified_time":"2019-01-13T15:38:48+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png","type":"image\/png"}],"author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer","datePublished":"2017-07-03T22:00:00+00:00","dateModified":"2019-01-13T15:38:48+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/","url":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/","name":"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2017-07-03T22:00:00+00:00","dateModified":"2019-01-13T15:38:48+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/04-07-17-noxxon-announces-first-patients-treated-in-phase-i-ii-clinical-trial-of-nox-a12-combined-with-keytruda-in-metastatic-pancreatic-and-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2530"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2530"}],"version-history":[{"count":3,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2530\/revisions"}],"predecessor-version":[{"id":2647,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2530\/revisions\/2647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}